Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 9 studies | 30% ± 13% | |
endothelial cell | 6 studies | 25% ± 9% | |
astrocyte | 5 studies | 27% ± 7% | |
microglial cell | 4 studies | 28% ± 6% | |
glutamatergic neuron | 4 studies | 37% ± 15% | |
neuron | 3 studies | 24% ± 12% | |
cardiac muscle cell | 3 studies | 24% ± 4% | |
GABAergic neuron | 3 studies | 35% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 34% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6186.94 | 1441 / 1445 | 100% | 27.79 | 183 / 183 |
intestine | 100% | 5986.51 | 966 / 966 | 99% | 18.87 | 523 / 527 |
stomach | 99% | 4925.49 | 357 / 359 | 99% | 19.04 | 283 / 286 |
brain | 99% | 5949.72 | 2620 / 2642 | 99% | 25.05 | 697 / 705 |
skin | 99% | 8417.95 | 1788 / 1809 | 99% | 22.42 | 468 / 472 |
breast | 100% | 5816.03 | 459 / 459 | 98% | 16.25 | 1092 / 1118 |
pancreas | 99% | 3409.04 | 326 / 328 | 98% | 18.81 | 174 / 178 |
lung | 99% | 4371.00 | 572 / 578 | 97% | 14.69 | 1121 / 1155 |
kidney | 100% | 3341.88 | 89 / 89 | 96% | 12.78 | 861 / 901 |
bladder | 100% | 4400.57 | 21 / 21 | 95% | 12.96 | 480 / 504 |
liver | 100% | 7296.64 | 226 / 226 | 95% | 17.94 | 384 / 406 |
prostate | 99% | 4592.94 | 243 / 245 | 93% | 9.43 | 468 / 502 |
uterus | 100% | 6748.95 | 170 / 170 | 92% | 13.51 | 422 / 459 |
thymus | 100% | 4205.74 | 650 / 653 | 92% | 9.65 | 558 / 605 |
ovary | 100% | 3641.22 | 180 / 180 | 80% | 8.23 | 342 / 430 |
adrenal gland | 92% | 2350.48 | 237 / 258 | 73% | 6.06 | 167 / 230 |
adipose | 100% | 4916.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 41089.82 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5024.75 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.35 | 1 / 1 |
blood vessel | 100% | 6196.16 | 1329 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 23.09 | 79 / 80 |
tonsil | 0% | 0 | 0 / 0 | 96% | 16.38 | 43 / 45 |
heart | 95% | 11913.11 | 822 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 13.14 | 26 / 29 |
peripheral blood | 88% | 3853.91 | 822 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1903028 | Biological process | positive regulation of opsonization |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_0090164 | Biological process | asymmetric Golgi ribbon formation |
GO_0031032 | Biological process | actomyosin structure organization |
GO_0048194 | Biological process | Golgi vesicle budding |
GO_0050714 | Biological process | positive regulation of protein secretion |
GO_0007030 | Biological process | Golgi organization |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0006259 | Biological process | DNA metabolic process |
GO_0006915 | Biological process | apoptotic process |
GO_0016477 | Biological process | cell migration |
GO_0090161 | Biological process | Golgi ribbon formation |
GO_0032982 | Cellular component | myosin filament |
GO_0016020 | Cellular component | membrane |
GO_0005815 | Cellular component | microtubule organizing center |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0009986 | Cellular component | cell surface |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016460 | Cellular component | myosin II complex |
GO_0005793 | Cellular component | endoplasmic reticulum-Golgi intermediate compartment |
GO_0005737 | Cellular component | cytoplasm |
GO_0042641 | Cellular component | actomyosin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0043531 | Molecular function | ADP binding |
GO_0051015 | Molecular function | actin filament binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0008094 | Molecular function | ATP-dependent activity, acting on DNA |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
GO_0003674 | Molecular function | molecular_function |
Gene name | MYO18A |
Protein name | Myosin XVIIIA Unconventional myosin-XVIIIa (Molecule associated with JAK3 N-terminus) (MAJN) (Myosin containing a PDZ domain) (Surfactant protein receptor SP-R210) (SP-R210) Putative TGFB1-induced anti-apoptotic factor 1 (12 kDa TGF-beta-1-induced antiapoptotic factor) |
Synonyms | TIAF1 MYSPDZ KIAA0216 CD245 |
Description | FUNCTION: May link Golgi membranes to the cytoskeleton and participate in the tensile force required for vesicle budding from the Golgi. Thereby, may play a role in Golgi membrane trafficking and could indirectly give its flattened shape to the Golgi apparatus . Alternatively, in concert with LURAP1 and CDC42BPA/CDC42BPB, has been involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration . May be involved in the maintenance of the stromal cell architectures required for cell to cell contact (By similarity). Regulates trafficking, expression, and activation of innate immune receptors on macrophages. Plays a role to suppress inflammatory responsiveness of macrophages via a mechanism that modulates CD14 trafficking . Acts as a receptor of surfactant-associated protein A (SFTPA1/SP-A) and plays an important role in internalization and clearance of SFTPA1-opsonized S.aureus by alveolar macrophages . Strongly enhances natural killer cell cytotoxicity . . FUNCTION: [Isoform TIAF1]: Inhibits the cytotoxic effects of TNF-alpha and overexpressed TNF receptor adapters TRADD, FADD, and RIPK1. Involved in TGF-beta1 inhibition of IkappaB-alpha expression and suppression of TNF-mediated IkappaB-alpha degradation. . |
Accessions | ENST00000530254.6 O95411 ENST00000533420.3 ENST00000528564.2 A0A1B0GV45 ENST00000704659.1 E9PN42 A0A1B0GWJ6 ENST00000533112.5 [Q92614-3] A0A994J771 ENST00000588791.1 Q92614 K7EKB3 H0YEV9 ENST00000527372.7 [Q92614-1] ENST00000636100.1 ENST00000531253.5 [Q92614-4] |